Dose-dense Biweekly Docetaxel, Oxaliplatin and 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase II study to evaluate the efficacy and safety of biweekly
docetaxel, Oxaliplatin and de Gramont regimen on unresectable gastric adenocarcinoma in the
first-line therapy.